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Traumatic injury to the central nervous system (CNS) is further complicated by an increase in secondary neuronal damage imposed by
activated microglia/macrophages. MicroRNA-124 (miR-124) is responsible for mouse monocyte quiescence and reduction of their
inflammatory cytokine production. We describe the formulation and ex vivo transfection of chitosan/miR-124 polyplex particles into rat
microglia and the resulting reduction of reactive oxygen species (ROS) and TNF-α and lower expression of MHC-II. Upon microinjection
into uninjured rat spinal cords, particles formed with Cy3-labeled control sequence RNA, were specifically internalized by OX42 positive
macrophages and microglia cells. Alternatively particles injected in the peritoneum were transported by macrophages to the site of spinal
cord injury 72h post injection. Microinjections of chitosan/miR-124 particles significantly reduced the number of ED-1 positive macrophages
in the injured spinal cord. Taken together, these data present a potential treatment technique to reduce inflammation for a multitude of CNS
neurodegenerative conditions.
From the Clinical Editor: The treatment of spinal cord injury remains an unresolved problem. Secondary damage is often the result of
inflammation caused by activated microglia and/or macrophages. In this article, the authors developed their formulation of chitosan/miR-124
polyplex particles and investigated their use in the suppression of neuronal inflammation. This exciting data may provide a new horizon for
patients who suffer from spinal cord injury.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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spinal cord injury (SCI) are approximated at 40 cases/million
people, and in the United States alone, 240-337,000 people are
currently living with a SCI.1 Regeneration of injuries in the CNS
are hampered by a number of inhibitory proteins and the glial
scar - a physical obstruction made up of extracellular matrix
created by fibroblasts and hypertrophic astrocytes which respond
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models of spinal cord injury. Nanomedicine: NBM 2016;12:643-653, http://dxDuring development, microglia arise from hematopoietic stem
cells, common myeloid progenitors, and erythromyeloid precur-
sors, at which point they spatially and functionally separate from
their mononuclear phagocyte relatives.3,4 Macrophages are the
effector cells in the inflammatory response at CNS lesions and are
derived from microglia and hematogenous monocytes, which are
functionally indistinguishable by their morphology and antigenic
markers. Therefore, in the context of CNS injury, activated
microglia are referred to as macrophages/microglia.
Activated macrophages/microglia are a chronic source of
many cytotoxic substances, such as the pro-inflammatory
cytokine, tumor necrosis factor alpha (TNF-α),5 inducible nitric
oxide synthase (iNOS),6 hypochlorous acid,7 and reactive
oxygen species (ROS).8 After the initial insult, secondary
inflammation occurs, which leads to enhanced damage to the
tissue in the form of neurodegeneration and impaired regener-
ation. Indeed, several studies involving anti-inflammatory
treatment after trauma, implicate classically activated (M1
polarized) macrophages/microglia as instigators of secondaryunder the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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crete large amounts of matrix metalloproteases (MMPs), which
contribute to degradation of the vascular basement membrane,
leading to increased permeability for infiltrating inflammatory
cells.12 Reactive microgliosis after SCI is a condition that
describes the self-perpetuating cycle of initial neuron damage,
myelin debris activating microglia, which in turn up-regulates
pro-inflammatory cytokines and neurotoxic molecules, thereby
causing more tissue damage and continuing the cycle of
activation/disruption.13–15 Therefore, similar to other neurode-
generative diseases, SCIs are progressive conditions caused by
an increase in secondary neuronal damage due to chronic
activation of microglia/macrophages. While it is environmental-
ly favorable for M1 macrophages to maintain an active state by
TNF-α positive feedback, they do maintain plasticity if their
cytokine environment changes.16 There is currently no effective
treatment for SCI, but modulation of macrophage state of
activation could have a positive effect by reducing the secondary
tissue damage.
Unraveling the roles of micro-RNA (miRNA) in cells has
given us more insight into the phenotypic regulation of cells
during development and disease states. Similar to small
interfering RNA (siRNA), miRNAs are ~23nt long endogenous
ribonucleic acid species that specifically pair with target mRNAs
post-transcriptionally to direct mRNA degradation machinery
and repress protein translation.17 miRNA-124, known as the
most abundant miRNA found in neurons, is associated with
promoting neuronal differentiation in neural progenitor
cells.18,19 It has also been shown to mediate microglia
quiescence by controlling two central transcription factors,
CCAAT/enhancer binding protein-alpha (C/EBP-alpha) and its
downstream target PU.1.20 These factors are involved in the
developmental regulation of non-myeloid cells, specifically, the
fibroblast – macrophage transition.21,22 miRNA-124 has
multiple target sites in the 5′ and 3′ UTR of C/EBP-alpha and
it was subsequently discovered that miRNA-124 is highly
expressed in resident microglia while being down regulated in
inflamed tissue.20,23 As such, the administration of miR-124 to
monocytes is associated with decreased levels of TNF-α, and
iNOS.20,24 It has been shown that miR-124 specifically regulates
TNF-α production via its targeting of signal transducer and
activator of transcription 3 (STAT3), which in turn decreases
production of TNF-α converting enzyme (TACE).25
Delivery of naked miRNAmimics (in the form of a siRNA) to
tissues is hampered by endogenous RNase degradation and poor
transfection efficiency/uptake into cells. There are many
solutions available for researchers to introduce RNAi into
cells, but the majority of commercial reagents are not cell
type-specific. As such, there is a need for the targeted delivery of
RNAi to cells and tissues to affect disease states without
interfering with gene expression in other cells. A simple system,
which has some level of cell selectivity, is the chitosan polyplex
carrier system.
Chitosan is a linear disaccharide made of D-glucosamine and
N-acetyl-D-glucosamine and is derived from the de-acetylation
of the naturally abundant chitin found in crustacean exoskele-
tons. As chitosan is a positively charged molecule of varying
sizes, it conveniently interacts with negatively charged doublestranded RNA to form polyplexes.26 The ratios of the two
components (the N/P ratio) can be varied to control surface
charge and size of the particles.26,27 Chitosan/siRNA particles
have been extensively employed as a non-toxic siRNA delivery
vehicle to a number of cell types.26,28–31 However, a transfection
preference for mononuclear phagocytes has been demonstrated
for murine peritoneal macrophages in models of radiation
induced fibrosis and arthritis.29,31
In the present study we employ the chitosan/siRNA polyplex
system to introduce a miRNA-124 mimic into rat microglia ex
vivo and in vivo using a model for traumatic spinal cord injury
with the goal of reducing/preventing the inflammatory effects
and secondary neuron damage induced by the activated
microglia/macrophage secretome in the spinal cord. Due to the
intrinsically invasive nature of local injections, an intraperitoneal
administration of particles to a rat spinal hemisection model is
also assessed.Methods
Preparation of chitosan polyplex particles
All chitosan (250 kDa, 150 kDa and 30 kDa) was purchased
as 95% de-acetylated from Heppe Medical Chitosan GMbH
(Frankfurt, Germany) and used to prepare polyplexes as
described previously.32 Briefly, chitosan is dissolved in acetate
buffer (300 mM, pH 5.5) overnight and filtered through a 0.2 μm
syringe filter to obtain a 1 mg ml−1 solution. To create particles,
Cy3™ dye-labeled siRNA specific to enhanced green fluores-
cent protein (sense 5′-GACGUAAACGGCCACAAGUUC-3′,
and antisense, 3′-CGCUGCAUUUGCCGGUGUUCA-5′),
miRNA precursor negative control #1 (AM17129, Life Tech-
nologies) or pre-miR™ miRNA precursor, miR-124 (AM17100,
life technologies) were each diluted in acetate buffer, and
chitosan solution was added to the calculated N:P (N:P 50) molar
ratio while stirring for 1 h at room temperature. Particles
formulated using eGFP siRNA-Cy3, AM17129 and AM17100,
are hereafter referred to as siRNA-Cy3, miR-CTRL, and
miR-124, respectively. Chitosan particle formulations were
analyzed for their hydrodynamic diameter by photon correlation
spectroscopy, and zeta potential by laser doppler velocimetry
(LDV) using a Zetasizer Nano ZS (Melvern Instruments,
Malvern, U.K.).
Ex vivo experiments
Neonatal rat microglia isolation
Microglia were isolated with modifications to existing
methods by mechanically homogenizing the CNS tissue of
neonatal rats.33,34 Briefly, neonatal P4-5 Wistar Hannover rats
were sacrificed by exposure to CO2 and decapitated. Brains and
spinal cords where extracted using standard techniques and
placed in phosphate buffered saline with 0.2 % glucose (PBSg).
The meninges were removed using a micro-dissection micro-
scope and microsurgical forceps. The CNS tissue was cut into
pieces and homogenized using a 15 ml wheaton® dounce tissue
homogenizer along with 5 ml of PBSg per brain/spinal cord. The
homogenate was filtered with a 40 μm falcon cell strainer
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Percoll® (Sigma-Aldrich, St. Louis, USA) in PBSg and overlaid
with 1.045 g cm−2 Percoll® in PBSg. After centrifugation at
1250×g for 45 min with minimum brake and acceleration in a
swinging bucket rotor, the purified microglia are located at the
Percoll® gradient's interface. Microglia were washed of Percoll®
and suspended in growth medium composed of DMEM (Gibco,
Life Technologies) supplemented with 10% performance plus
endotoxin free, certified fetal bovine serum (Gibco, Life
Technologies) with penicillin/streptomycin (Gibco, Life Tech-
nologies) and plated as required. Isolated cell purity was assessed
by flow cytometric analysis. For flow cytometry experiments,
microglia were seeded at a density of 0.5×105 per well in 6 well
plates. To activate the microglia, cultures were treated with 20 ng
ml−1 interferon gamma (IFN-γ), and 100 ng ml−1 lipopolysac-
charide (LPS) and for 1 h and 24 h, respectively, after which, the
cells were washed and the media replaced daily.
Polyplex cytotoxicity assay
Microglia were seeded in a 96-well plate at a density of
5 × 104 cells perwell in 100μl growthmedium.AlamarBlue® (Life
Technologies) was used according to the manufacturer's guidelines
to assess viability of microglia after a 48 h treatment with Chitosan/
miRNA particles. Absorbance was measured at 570 nm using a
FLUOstar OPTIMA (BMG Labtech, Offenburg, Germany).
Polyplex uptake studies
Isolated primary microglia were plated at 5 × 104 cells/well in
8 well chamber slidesTM (Sigma-Aldrich, Cat# C7182) for 48 h
and transfected with chitosan/Cy-3 particles for 2 h. Cells were
washed in cold PBS with 1% sodium azide, stained using wheat
germ agglutinin Alexa Fluor® 488 (WGA-A488) conjugate (Life
Technologies) as per manufacturer's instructions and fixed in 4%
paraformaldehyde (Electron Microscopy Sciences). Coverslips
were mounted using Prolong Gold® with DAPI (Life Technol-
ogies), and slides were imaged with a LSM 700 confocal laser
scanning microscope (Zeiss, Germany) using the 63×/1.4 oil
objective with 8-bit depth. Fluorescence signals were captured
within the dynamic range of the signal intensity and background
was corrected by ImageJ (http://rsbweb.nih.gov/ij/, National
Institutes of Health, USA).
Microglia supernatant assays
Microglia were isolated and expanded in 6 well plates in
growth media with added 5 ng ml−1 granulocyte macrophage
colony stimulating factor (GM-CSF) (R&DSystems,Minneapolis,
MN, U.S.A.). Cells were activated using IFN-γ and LPS and
treated with particles for 2 h; termination of the experiment
occurred 48 h post-transfection. All supernatants were collected
during media changes each day and frozen at -80 °C for analysis.
A Greiss® reagent kit (Molecular Probes) for nitrite species
quantification was used according to manufacturer's instruc-
tions. Absorbance was quantified at 540 nm using a FLUOstar
OPTIMA plate reader (BMG Labtech). Secreted TNF-α was
quantified using an enzyme linked immunosorbent assay
(ELISA) kit (Life Technologies) according to the manufac-
turer's instructions, and quantified by measuring absorbance at
485 nm using a FLUOstar OPTIMA plate reader (BMG
Labtech).Flow cytometry
Cells were washed twice before harvesting by gentle scraping
and pelleted by centrifugation. Microglia were suspended at a
concentration of 0.5 × 106 cells per sample and blocked for 10
min using 5% mouse serum in flow buffer (FB) (PBS containing
0.5% bovine serum albumin, and 1% sodium azide). Blocking
medium was removed and the cells were immuno-labeled at 4 °C
for 45 min in 100 μl FB containing antibodies. Mouse anti-rat
antibodies, PE anti-rat RT1B (OX6) and Alexa Fluor® 488
anti-rat CD11b (Ox-42) were purchased from Biolegend, San
Diego, CA, USA and titrated to determine appropriate final
concentrations. After incubation, cells were washed three times
and suspended in 500 μl flow buffer and analyzed on a Gallios™
flow cytometer (Becton Dickenson, San Jose, CA). Single cell
analysis was assured by gating the dominant population from
forward scatter time of flight versus forward scatter peak. This
population was subsequently gated for morphology using
standard techniques. Quadrant gating for fluorescent channels
was performed using standard fluorescence minus one (FMO)
control techniques. Fluorescent cytometric data was analyzed
using Kaluza software (Becton Dickenson, San Jose, CA).
In vivo experiments
Experimental animals
The experiments were performed on adult (16 weeks old, n =
32) female Sprague-Dawley rats (Charles River Laboratories,
Germany). The animal care and experimental procedures were
carried out in accordance with Directive 2010/63/EU of the
European Parliament and of the Council on the protection of
animals used for scientific purposes, and were also approved by
the Northern Swedish Committee for Ethics in Animal
Experiments (No. A36-12). All surgical procedures were
performed under general anaesthesia using a mixture of ketamine
(Ketalar, Parke-Davis; 100 mg/kg i.v.) and xylazine (Rompun®,
Bayer; 10mg/kg i.v.). After surgery, the rats were given the
analgesic, Finadyne (Schering-Plough, Denmark; 2.5 mg/kg,
s.c.), normal saline (4 ml, s.c.) and benzylpenicillin (Boehringer
Ingelheim; 60 mg, i.m.). Each animal was housed alone in a cage
after surgery and exposed to 12 h light/dark cycles, with free
access to food and water.
Injection of polyplex particles
For injections of particles into the normal spinal cord, cervical
C3-C4 laminectomy was performed and rats were mounted in a
stereotaxic frame (Stoelting's Lab Standard Stereotaxic Instru-
ment, Stoelting Co., USA). A glass micropipette (outer tip
diameter 70 μm) was attached to a 5 μl Hamilton syringe, filled
with 35 ng μl−1 miRNA particles suspended in acetate buffer pH
5.5, and 1 μl of particles was slowly (10 minutes) pressur-
e-injected into the lateral funiculus (depths 1.0 mm) in 3 sites
along the rostro-caudal axis of the C3-C4 spinal segments at
approximately 1 mm from each other. The micropipette was left
in place for additional 2–3 min. Dura mater was covered with
Spongostan®, muscles and skin were closed in layers.
For injections of particles in animals with spinal cord injury,
the C3 spinal cord segment was exposed and transected on the
left side with fine scissors under an operating microscope. The
lesion included the lateral funiculus as well as the adjacent grey
Figure 1. Chitosan particle characterization by photon correlation spectroscopy and laser Doppler velocimetry (LDV). Representative histograms of particle
radius and dispersity (A). The size (diameter in nm), polydispersity index (PDI) and zeta potential of the particles (B).
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(depths 1.0 mm) at approximately 1 mm rostral and 1 mm caudal
to the lesion site as described above. For intraperitoneal
injections, 1 ml solution of particles labelled with Cy-3 was used.
In a separate group of animals, the trauma zone was
expanded in the rostro-caudal direction by gentle aspiration to
create a 1–2 mm long cavity in the C3 spinal segment. A small
piece of Spongostan® was soaked in 1 μl of 35 ng μl−1 miRNA
particles suspended in acetate buffer pH 5.5 and implanted into
the cavity. The injury site was covered with fibrin glue (Tisseel®
Baxter SA, Switzerland) and muscles and skin were closed in
layers.
Tissue processing
At 3 h, 24 h, 2 days, 3 days and 7 days, the animals were
deeply anaesthetized with an intraperitoneal overdose of sodium
pentobarbital and transcardially perfused with Tyrode's solution
followed by 4% paraformaldehyde in 0.1 M phosphate buffer
(pH 7.4). Spinal cord segments C2–C5 were removed and
transferred into the same fixative for 3–4 h. Tissue blocks were
then cryoprotected in 10% and 20% sucrose for 2–3 days and
frozen in liquid isopentane. Serial longitudinal 16-μm-thick
sections were cut on a cryomicrotome (Leica Instruments,
Germany), thaw-mounted in pairs onto SuperFrost™ Plus
slides, dried overnight at room temperature and stored at −85 °C
before processing.
Immunohistochemistry
After blocking with normal serum, the following primary
antibodies were used: rabbit anti-GFAP (1:1000; Dako), mouse
anti-ED-1 (1:100, Abcam), mouse anti-OX-42 (1:250; Serotec),
mouse anti-NeuN (1:200; Chemicon). All primary antibodies
were applied for 2 h at room temperature. After rinsing in PBS,
secondary goat anti-mouse and goat anti-rabbit antibodies AlexaFluor® 488 and Alexa Fluor® 568 (1:300; Molecular Probes,
Invitrogen) were applied for 1 h at room temperature in the dark.
The slides were mounted with ProLong® mounting media
containing DAPI (Invitrogen). The staining specificity was tested
by omission of primary antibodies.
Quantification of macrophage/microglial reaction
Reaction of ED1-positive macrophages and microglial cells
was studied in the spinal cord trauma zone in 20 randomly
selected sections after injection of particles containing miR-
NA-CTRL or microRNA-124. The images were captured at 400
final magnifications and 1280×1024 pixels resolution with a
Nikon DS-U2 digital camera, imported into Image-Pro Plus
software (Media Cybernetics, Inc, USA) and the relative tissue
area occupied by labelled profiles was quantified.
Statistical analysis
One-way analysis of variance (ANOVA) followed by a post
hoc Newman-Keuls Multiple Comparison Test and unpaired
t-test were used to determine statistical differences between
the experimental groups (Prism®, GraphPad Software, Inc,
USA).Results
Characterization of chitosan polyplex particles
Chitosan particles formulated at N:P ratio 50 with either
miR-124 mimic (miR-124), a scrambled miRNA control mimic
(miR-CTRL), or a Cy3 labeled unrelated siRNA (siRNA-Cy3)
were evaluated for size, polydispersity and zeta potential
(Figure 1). The size of the particles formulated with the
miRNA precursors were similar to each other: 206.6 ± 6.6 nm
for miR-CTRL and 222.0 ± 16.71 nm for miR-124 while the
Figure 2. Representative confocal scanning laser microscopy images of untreated primary rat microglia (A–C) labelled with wheat germ agglutinin Alexa Fluor®
488 conjugate (WGA, green) and DAPI (blue), and images showing intracellular uptake of chitosan particles containing 5 μM (D–F), 25 μM (G–I), 50 μM
(J–L) of siRNA-Cy3 (red) after 2 h treatment. Arrows indicate examples of external chitosan agglomerates. Scale bar, 20 μm.
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size (158.1 ± 19.4 nm; Figure 1, A). The polydispersity index
showed a narrow distribution of particle sizes for miR-Cy3,
miR-CTRL, and miR-124 (0.286 ± 0.071, 0.246 ± 0.069, and
0.303 ± 0.061, respectively). The zeta potential of the particles
formulated with the miRNA precursors were similar 17.6–
18.6 whereas the siRNA-Cy3 loaded particles was slightly
lower most likely due to the added contribution of negative
charges from the two sulfonate groups on Cy3 (Figure 1, B).Uptake of particles in primary microglia
siRNA-Cy3/chitosan complexes, formed with variable N:P
ratios and molecular weights of chitosan (30, 150, and 250 kDa)
were screened for their uptake into primary microglia (data not
shown). Of these, a complex formed with 150 kDa chitosan at
N:P ratio of 50 was determined to be optimal for transfecting
activated primary microglia. Representative fluorescent images
of siRNA-Cy3/chitosan particle uptake after 2 hours can be seen
Figure 3. Isolated microglia were expanded with GM-CSF, activated using
LPS and IFN-γ, and treated with miR/chitosan particles. Cells were
incubated with particles for 48 h with three different miRNA concentrations.
Cytotoxicity of chitosan/miRNA particles measured by AlamarBlue®
viability assay (A). Percent viability is expressed relative to untreated
controls ± SD (n=3). Activated microglia supernatant assays (B, C). Total
supernatant was harvested each day for analysis by TNF-α ELISA (B) and
Greiss nitrite assay (C). Results indicate concentrations 48 h after particle
treatment. ** and *P b 0.01 and 0.05 versus LPS and IFN-γ alone (n=3).
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were stained using WGA-A488 and internalization of increasing
concentrations of chitosan/siRNA-Cy3 can be seen in the merged
images. The advantage of using WGA-fluorescent conjugates to
visualize cell membranes is multifarious because it binds to
n-acetyl-d-glucosamine which is a monomeric unit of chitosan.
Therefore, by ensuring that the cell membrane stays imperme-
able to the WGA-A488 (by fixing the sample after staining), the
overlaid image can indicate internal (red Cy3 fluorescence) vs.
external (co-localized green and red fluorescence (yellow))
chitosan particles in the merged images (Figure 2, arrows). This
was subsequently confirmed by CLSM z-stack images (Supple-
mental Figure 1).The toxicity of the particle treatment was evaluated after 48 h
incubation by AlamarBlue® staining. Notably, the primary
microglia showed no significant decrease in viability after
treatment with chitosan particles (Figure 3, A).
Polyplex particles mediated reduction of inflammatory factors
Next we investigated the effect of particle treatment on
production of TNF- α and nitrite species. Secreted TNF-α was
quantified by ELISA and the inducible nitric oxide synthase
(iNOS) activity was assessed by measuring nitrite concentration
in the cell culture media. When activated with IFN-γ and LPS,
microglia secreted an increased amount of TNF-α and nitrite
compared to inactive controls, 126.4 ± 11.6 pg ml−1 versus 4.9 ±
3.6 pg ml−1 and 22.9 ± 2.3 μM versus 0.75 ± 0.6 μM,
respectively (Figures 3, B and C). Upon transfection with 5, 25
and 50 nM of chitosan/miR-124 particles, the increase in TNF-α
secretion was reduced 16.4%, 30.7% (Pb0.01) and 45%
(Pb0.01), respectively, compared to miR-CTRL particles
(Figure 3, B). Concurrently, transfection with 25 nM or 50 nM
miR-124 particles, reduced the production of nitrite by
activated microglia by 51.6% and 64%, respectively (Pb0.01,
Figure 3, C).
Flow cytometry of microglia
Expanded primary microglia were activated and treated with
50 nM miRNA containing chitosan particles. Prior to the
treatment microglia culture purity was N96% estimated by the
microglial marker CD11b. Activated (IFN-γ and LPS) cultures
were ~94% MHC-II positive and only ~1% of cells were
MHC-II positive in normal (inactive) cultures (Figure 4). After
48 h treatment with particles containing miR-CTRL, 90% of the
cells showed little change compared to activated controls.
Treatment with chitosan/miR-124 particles resulted in ~50%
fewer MHC-II positive cells, compared to miR-CTRL particles.
Expression of CD11b stayed constant for all samples. This data
shows that transfection of miRNA-124 particles with concurrent
M1 induction was able to maintain lowMHC-II expression in the
culture, thereby reducing the number of M1 activated cells in the
presence of strong polarizing factors.
Polyplex particle application in spinal cord injury model
Three to seventy-two hours after microinjections of chitosan
formulated siRNA-Cy3 particles into C3-C4 segments of normal
spinal cord, the Cy3 signal could be detected at the injection sites
(Figure 5, A, D, G) in the form of small bright round spots (see
insertion in Figure 5, A) and as a diffuse staining of the
surrounding spinal cord parenchyma. The siRNA-Cy3 signal,
appears to increase within the first 48 h (data not shown), this
may be due to scavenging activity of activated macrophages and
microglial cells concentrating the particles in endosomes.
Additional immunostaining with antibodies against glial and
neuronal markers (Figure 5, B, E, H) revealed that OX42
positive macrophages and microglial cells have a preference to
internalize the particles (Figure 5, B, C). In contrast, the GFAP
positive processes of astrocytes (Figure 5, E, F) and NeuN
positive neuronal cell bodies (Figure 5, H, I) did not show any
co-localisation with Cy3.
Figure 4. Flow cytometry analysis of MHC-II (y-axis) and CD11b (x-axis) expression in non-activated (Control), activated (Vehicle), and activated microglia
treated with chitosan/miR-124 or miR-CTRL particles. Upper quadrants represent MHC-II-positive cells.
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toneal injection of chitosan formulated siRNA-Cy3 particles,
small clusters of Cy3/ED-1 positive activated macrophages were
found within 300-500 μm rostral and caudal to the injury site
(Figure 5, J-L). The Cy3 signal in these blood-born macrophages
appeared both as granular and diffuse staining (Figure 5, J).
Effects of miR-124 chitosan particles on macrophage/microglia
reaction
Microinjection of 1 μL chitosan formulated miR-CTRL
particles into intact cervical C3 spinal cord of adult rats induced
activation of ED-1 positive macrophages and microglial cells
along the injury canal left after withdrawal of the 70 μm thick tip
of the glass micropipette (Figure 6, A, C). In contrast, injection
of particles with miR-124 reduced the number of ED-1 labelled
cells by 80% (Pb0.001; Figure 6, B, C).
In the experiments with spinal cord injury, the rats underwent
cervical C3 hemisection and chitosan formulated miR-CTRL
particles were injected 1 mm rostral and caudal to the injury site.
The reaction of ED-1 positive macrophages and microglial cells
was measured in the trauma zone. Injections of miR-124
containing particles reduced the number of ED-1 positive cells
by 60% (Pb0.001; Figure 7).
However, when miR-124 particles were introduced into the
spinal cord cavity within a small piece of Spongostan®, no
reduction in macrophage and microglia activity was found (data
not shown).Discussion
Active macrophages/microglia play a central role in traumatic
SCIs as well as in the progression of certain neurodegenerative
diseases, including Parkinson's disease,35 multiple sclerosis
(MS),36 and Alzheimer's disease.37 As such, reducing CNS
inflammation presents a promising strategy for treatment of
multiple neurodegenerative disorders. By administering miR-124/
chitosan polyplex particles in rat models of spinal cord
inflammation, we successfully altered the inflammatory response
by affecting the transcriptome of local macrophages/microglia.We describe formulations of non-toxic chitosan particles for
the effective delivery of miR-124. It has been previously
reported that uptake of 150–300 nm chitosan-DNA particles is
cell-type dependent.38 Our studies have demonstrated that
similar size chitosan particles can provide delivery of small
interfering RNA (siRNA) to different cell types and the efficacy
of uptake is also cell-type dependent and can vary based on the
MW and degree of deacetylation.27,31 The present results show
that ~160 nm siRNA-Cy3/chitosan particles have been taken up
by nearly all cultured macrophages and the functional efficiency
of the ~220 nmmiR-124/chitosan particles (based on the number
of MHC-II positive cells) was about 50%. Chitosan is known to
be an effective agent for siRNA complexation, and capable of
delivery to various types of macrophages.26,31,39 Although the
chitosan system does not specifically target any particular cell
type, they are shown here to be internalized solely by microglia/
macrophages in vivo. Transfection of cationic polyplexes
mediated by charge interactions between the positive surface
charge of the particle and the negatively charged cell membrane.
It is believed that chitosan particles transfect cells via endocytic/
phagocytic activity, and subsequently escape the endosome/
lysosome either by the “proton sponge effect”, or by the
degradation products of the polymer increasing the osmolality
and thereby rupturing the endosome.38,40 The innate specificity
for targeting macrophages/microglia with the miR-124 mimic
rather than astrocytes is important in that the regulation of
STAT3 in astrocytes can prevent the organization of the
astrocytic penumbra of the glial scar, which can lead to an
increased inflammation response.41–43
Our results support and complement a previous study in mice
showing that miR-124 transfection reduces MHC-II, TNF-α and
ROS production in bone marrow derived macrophages.20
However, as previous studies have alleged that certain MW of
chitosan have an effect on the polarization state of
macrophages,44,45 it is important to note that our results are
specifically dependent on the RNA sequence in complex with
chitosan, and not due to the chitosan itself.
While microinjections present a convenient model of CNS
inflammation simply due to the physical disruption of the blood
brain barrier (BBB) by the needle cavity, the clinical application
Figure 5. Horizontal spinal cord sections of C3 segments showing siRNA-Cy3/chitosan particles (Cy3) 3 days after injection into normal spinal cord (A–I) and
after intraperitoneal injection in animals with spinal cord injury (J–L). Sections were immunostained for OX42 (CD11b, macrophages and microglia), GFAP
(astrocytes), NeuN (neurons) and ED-1 (activated macrophages/microglia). Cell nuclei were stained using DAPI. Boxed area in (A) demonstrates details of
injection site with small bright round particles and diffuse staining. Note association of Cy3 labelled particles with OX42 and ED-1 positive cells. Scale bar, 50
μm (A–F), 100 μm (G–I) and 20 μm (J–L).
650 A.M. Louw et al / Nanomedicine: Nanotechnology, Biology, and Medicine 12 (2016) 643–653of such an invasive technique is minimal. Disruption of the BBB
during traumatic injury, Alzheimers disease,46 MS,47 and
Parkinsons disease 48 leads to a host of complications for CNS
repair, but can also provide an avenue for infiltration of
therapeutics from the blood stream. By loading macrophages
with particles containing catalase, and injecting them intraper-itoneally into an induced mouse model of Parkinson's disease,
particle loaded macrophages have been shown to localize in the
affected midbrain and protect neurons by reducing ROS
species.49 Chitosan particles have previously been found to be
transported with recruited macrophages to sites of inflammation in
a mouse models of rheumatoid arthritis,31 radiation induced
Figure 6. Horizontal sections of C3 spinal segments with ED-1 positive
macrophages and microglia 3 days after injection of miR-CTRL (A) and
miR-124 (B) chitosan particles into normal spinal cord. Histogram showing
the relative tissue area occupied by ED-1 positive macrophages and
microglial cells (C). Error bars show S.E.M. Pb0.001 is indicated by ***.
Scale bar, 50 μm.
651A.M. Louw et al / Nanomedicine: Nanotechnology, Biology, and Medicine 12 (2016) 643–653fibrosis,29,39 kidney fibrosis,50 and periodontal lesions.51 To
evaluate if the same mode of delivery is available for use in future
CNS inflammation studies, we surgically performed SCIs,
followed by intraperitoneal injection of chitosan particles to assess
the recruitment of the particle loaded macrophages to the injury
site. The migration of peritoneal macrophages to the spinal cord
lesion was validated by the detection of internalized chitosan/
siRNA-Cy3 particles. It remains to be seen if miR-124 can have
the same effect on macrophage activation in SCIs if delivered to
the peritoneum, as these cells may not be as motile when
quiescent.52,53 Additionally, motility may directly be affected
by miR-124 targeting STAT3, as this signaling pathway has
been shown to regulate cell movement in keratinocytes,
leukocytes, and epidermal cells.54 Regardless of the cargo,
this delivery strategy presents a promising, minimally invasive
means to address CNS inflammation in future studies and may
also provide a method of quantifying and studying the effects
and the resident vs. migratory macrophage population in such
conditions.The miR-124 particle treatment was effective in reducing
local ED-1 positive cells in an acute in vivo SCI model.
Long-term experiments are needed to study the effect miR-124/
chitosan particles may have on the secondary tissue disruption
associated with SCI. It is certainly conceivable from the evidence
presented that the marked reduction of ED-1 expressing
macrophages/microglia in miR-124 treated SCI's correlate with
a reduction in inflammatory secretome expression.
Polarization of microglia/macrophages to the activated M1
phenotype is linked to the sustained inflammatory conditions of
neurodegenerative diseases; the alternatively activated M2
phenotype performs the opposite function and enhances
neuroprotection and regeneration in SCI.55 Therefore the
strategy employed herein, to reduce neurotoxic agents in the
CNS by delivering miR-124 to induce macrophage quiescence,
has the potential to be enhanced further by exploring the
possibility of promoting M2 polarization over that of M1. As we
have successfully shown delivery of miRNA/particles to M1
activated macrophages/microglia and the subsequent reduction
of negative effects thereof, a similar strategy could be employed
to deliver a miRNA responsible for promoting the transition of
M1 to M2 polarization or by delivering an anti-miR to reduce the
effect of an M1 specific miRNAs. An anti-miR towards miR-155
could also be a viable option for delivery to SCIs as the miRNA
has been shown to promote M1 polarization in human
macrophages while its inhibition blunts the expression of
pro-inflammatory cytokines in a MS model.56 It has recently
been shown that miRNA let-7c promotes M2 polarization by
regulating C/EBP-δ in mouse bone marrow derived macro-
phages and is conversely associated with M1 polarization upon
silencing using anti-miRs.57
Taken together, our data presents the chitosan polyplex
system as a promising method for the delivery of miRNA to
specifically modulate macrophage/microglia activation, and
subsequently reduce neuroinflammation in vivo.Author Contributions
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Figure 7. Horizontal spinal cord sections of C3-C4 segments (A, B) immunostained for ED-1 positive macrophages and microglial cells 3 days after spinal cord
hemisection followed by intraspinal injection of miR-CTRL (A) and miR-124 (B) chitosan particles. Dotted lines indicate primary trauma zone. Boxed areas in
(A) and (B) are enlarged in (C) and (D), respectively. Note significant reduction of ED-1 immunostaining in (B). Histogram showing the relative tissue area
occupied by ED-1 positive macrophages and microglial cells (E). Error bars show S.E.M. Pb0.001 is indicated by ***. Scale bar, 500 μm.
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